These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29552709)

  • 1. Use of calcimimetics in children with normal kidney function.
    VanSickle JS; Srivastava T; Alon US
    Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
    Nemeth EF; Shoback D
    Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
    Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
    Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulators of the extracellular calcium receptor.
    Nemeth EF
    Drug Discov Today Technol; 2013; 10(2):e277-84. PubMed ID: 24050279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet.
    Reh CM; Hendy GN; Cole DE; Jeandron DD
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E707-12. PubMed ID: 21289269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
    Massy ZA; Hénaut L; Larsson TE; Vervloet MG
    Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calcium-sensing receptor and calcimimetics in blood pressure modulation.
    Smajilovic S; Yano S; Jabbari R; Tfelt-Hansen J
    Br J Pharmacol; 2011 Oct; 164(3):884-93. PubMed ID: 21410453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
    Hénaut L; Boudot C; Massy ZA; Lopez-Fernandez I; Dupont S; Mary A; Drüeke TB; Kamel S; Brazier M; Mentaverri R
    Cardiovasc Res; 2014 Feb; 101(2):256-65. PubMed ID: 24217682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcimimetics and calcilytics--fooling the calcium receptor.
    Steddon SJ; Cunningham J
    Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.
    Nemeth EF; Goodman WG
    Calcif Tissue Int; 2016 Apr; 98(4):341-58. PubMed ID: 26319799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues.
    Quarles LD
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):349-55. PubMed ID: 12815330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic use of calcimimetics.
    Hebert SC
    Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.